FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact
Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:FAM65A-EGFR (FusionGDB2 ID:29052)

Fusion Gene Summary for FAM65A-EGFR

check button Fusion gene summary
Fusion gene informationFusion gene name: FAM65A-EGFR
Fusion gene ID: 29052
HgeneTgene
Gene symbol

FAM65A

EGFR

Gene ID

79567

1956

Gene nameRHO family interacting cell polarization regulator 1epidermal growth factor receptor
SynonymsFAM65AERBB|ERBB1|HER1|NISBD2|PIG61|mENA
Cytomap

16q22.1

7p11.2

Type of geneprotein-codingprotein-coding
Descriptionrho family-interacting cell polarization regulator 1family with sequence similarity 65 member Aprotein FAM65Aepidermal growth factor receptoravian erythroblastic leukemia viral (v-erb-b) oncogene homologcell growth inhibiting protein 40cell proliferation-inducing protein 61epidermal growth factor receptor tyrosine kinase domainerb-b2 receptor tyrosine kinas
Modification date2020031320200329
UniProtAcc.

P00533

Ensembl transtripts involved in fusion geneENST00000379312, ENST00000566522, 
ENST00000042381, ENST00000540839, 
ENST00000422602, ENST00000428437, 
ENST00000455089, ENST00000342916, 
ENST00000344576, ENST00000420316, 
ENST00000275493, ENST00000442591, 
ENST00000463948, ENST00000454757, 
Fusion gene scores* DoF score6 X 11 X 3=19817 X 20 X 8=2720
# samples 1522
** MAII scorelog2(15/198*10)=-0.400537929583729
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(22/2720*10)=-3.62803122261304
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: FAM65A [Title/Abstract] AND EGFR [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointFAM65A(67576379)-EGFR(55269015), # samples:1
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneEGFR

GO:0001934

positive regulation of protein phosphorylation

20551055

TgeneEGFR

GO:0007165

signal transduction

10572067

TgeneEGFR

GO:0007166

cell surface receptor signaling pathway

7736574

TgeneEGFR

GO:0007173

epidermal growth factor receptor signaling pathway

7736574|12435727

TgeneEGFR

GO:0008283

cell proliferation

17115032

TgeneEGFR

GO:0008284

positive regulation of cell proliferation

7736574

TgeneEGFR

GO:0010750

positive regulation of nitric oxide mediated signal transduction

12828935

TgeneEGFR

GO:0018108

peptidyl-tyrosine phosphorylation

22732145

TgeneEGFR

GO:0030307

positive regulation of cell growth

15467833

TgeneEGFR

GO:0042177

negative regulation of protein catabolic process

17115032

TgeneEGFR

GO:0042327

positive regulation of phosphorylation

15082764

TgeneEGFR

GO:0043406

positive regulation of MAP kinase activity

10572067

TgeneEGFR

GO:0045739

positive regulation of DNA repair

17115032

TgeneEGFR

GO:0045740

positive regulation of DNA replication

17115032

TgeneEGFR

GO:0045944

positive regulation of transcription by RNA polymerase II

20551055

TgeneEGFR

GO:0050679

positive regulation of epithelial cell proliferation

10572067

TgeneEGFR

GO:0050999

regulation of nitric-oxide synthase activity

12828935

TgeneEGFR

GO:0070141

response to UV-A

18483258

TgeneEGFR

GO:0070374

positive regulation of ERK1 and ERK2 cascade

20551055

TgeneEGFR

GO:0071392

cellular response to estradiol stimulus

20551055

TgeneEGFR

GO:1900020

positive regulation of protein kinase C activity

22732145

TgeneEGFR

GO:1903078

positive regulation of protein localization to plasma membrane

22732145


check buttonFusion gene breakpoints across FAM65A (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check buttonFusion gene breakpoints across EGFR (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check button Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChiTaRS5.0N/ABF844939FAM65Achr16

67576379

-EGFRchr7

55269015

-


Top

Fusion Gene ORF analysis for FAM65A-EGFR

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
In-frameENST00000379312ENST00000455089FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000379312ENST00000342916FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000379312ENST00000344576FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000379312ENST00000420316FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000379312ENST00000275493FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000379312ENST00000442591FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000379312ENST00000463948FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000379312ENST00000454757FAM65Achr16

67576379

-EGFRchr7

55269015

-
intron-3CDSENST00000566522ENST00000455089FAM65Achr16

67576379

-EGFRchr7

55269015

-
intron-intronENST00000566522ENST00000342916FAM65Achr16

67576379

-EGFRchr7

55269015

-
intron-intronENST00000566522ENST00000344576FAM65Achr16

67576379

-EGFRchr7

55269015

-
intron-intronENST00000566522ENST00000420316FAM65Achr16

67576379

-EGFRchr7

55269015

-
intron-intronENST00000566522ENST00000275493FAM65Achr16

67576379

-EGFRchr7

55269015

-
intron-intronENST00000566522ENST00000442591FAM65Achr16

67576379

-EGFRchr7

55269015

-
intron-intronENST00000566522ENST00000463948FAM65Achr16

67576379

-EGFRchr7

55269015

-
intron-intronENST00000566522ENST00000454757FAM65Achr16

67576379

-EGFRchr7

55269015

-
In-frameENST00000042381ENST00000455089FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000042381ENST00000342916FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000042381ENST00000344576FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000042381ENST00000420316FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000042381ENST00000275493FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000042381ENST00000442591FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000042381ENST00000463948FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000042381ENST00000454757FAM65Achr16

67576379

-EGFRchr7

55269015

-
In-frameENST00000540839ENST00000455089FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000540839ENST00000342916FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000540839ENST00000344576FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000540839ENST00000420316FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000540839ENST00000275493FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000540839ENST00000442591FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000540839ENST00000463948FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000540839ENST00000454757FAM65Achr16

67576379

-EGFRchr7

55269015

-
In-frameENST00000422602ENST00000455089FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000422602ENST00000342916FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000422602ENST00000344576FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000422602ENST00000420316FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000422602ENST00000275493FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000422602ENST00000442591FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000422602ENST00000463948FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000422602ENST00000454757FAM65Achr16

67576379

-EGFRchr7

55269015

-
In-frameENST00000428437ENST00000455089FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000428437ENST00000342916FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000428437ENST00000344576FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000428437ENST00000420316FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000428437ENST00000275493FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000428437ENST00000442591FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000428437ENST00000463948FAM65Achr16

67576379

-EGFRchr7

55269015

-
5CDS-intronENST00000428437ENST00000454757FAM65Achr16

67576379

-EGFRchr7

55269015

-

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000379312FAM65Achr1667576379-ENST00000455089EGFRchr755269015-264220011211257378
ENST00000042381FAM65Achr1667576379-ENST00000455089EGFRchr755269015-25771936681192374
ENST00000540839FAM65Achr1667576379-ENST00000455089EGFRchr755269015-278921481421404420
ENST00000422602FAM65Achr1667576379-ENST00000455089EGFRchr755269015-26652024181280420
ENST00000428437FAM65Achr1667576379-ENST00000455089EGFRchr755269015-26762035261291421

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000379312ENST00000455089FAM65Achr1667576379-EGFRchr755269015-0.0069805990.9930194
ENST00000042381ENST00000455089FAM65Achr1667576379-EGFRchr755269015-0.0038367990.99616325
ENST00000540839ENST00000455089FAM65Achr1667576379-EGFRchr755269015-0.0194621030.98053795
ENST00000422602ENST00000455089FAM65Achr1667576379-EGFRchr755269015-0.0186016040.9813984
ENST00000428437ENST00000455089FAM65Achr1667576379-EGFRchr755269015-0.0149108050.98508924

Top

Fusion Genomic Features for FAM65A-EGFR


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for FAM65A-EGFR


check button Go to

FGviewer for the breakpoints of chr16:67576379-chr7:55269015

.
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
.EGFR

P00533

FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes.FUNCTION: Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975, PubMed:15611079, PubMed:12297049, PubMed:27153536, PubMed:20837704, PubMed:17909029). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Plays a role in enhancing learning and memory performance (By similarity). {ECO:0000250|UniProtKB:Q01279, ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11116146, ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:11602604, ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12873986, ECO:0000269|PubMed:15374980, ECO:0000269|PubMed:15590694, ECO:0000269|PubMed:15611079, ECO:0000269|PubMed:17115032, ECO:0000269|PubMed:17909029, ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:20462955, ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:21258366, ECO:0000269|PubMed:27153536, ECO:0000269|PubMed:2790960, ECO:0000269|PubMed:7679104, ECO:0000269|PubMed:8144591, ECO:0000269|PubMed:9419975}.; FUNCTION: Isoform 2 may act as an antagonist of EGF action.; FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins. {ECO:0000269|PubMed:21516087}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneEGFRchr16:67576379chr7:55269015ENST00000275493028712_97901211.0DomainProtein kinase
TgeneEGFRchr16:67576379chr7:55269015ENST00000342916016712_9790629.0DomainProtein kinase
TgeneEGFRchr16:67576379chr7:55269015ENST00000344576016712_9790706.0DomainProtein kinase
TgeneEGFRchr16:67576379chr7:55269015ENST00000420316010712_9790406.0DomainProtein kinase
TgeneEGFRchr16:67576379chr7:55269015ENST00000275493028718_72601211.0Nucleotide bindingATP
TgeneEGFRchr16:67576379chr7:55269015ENST00000275493028790_79101211.0Nucleotide bindingATP
TgeneEGFRchr16:67576379chr7:55269015ENST00000342916016718_7260629.0Nucleotide bindingATP
TgeneEGFRchr16:67576379chr7:55269015ENST00000342916016790_7910629.0Nucleotide bindingATP
TgeneEGFRchr16:67576379chr7:55269015ENST00000344576016718_7260706.0Nucleotide bindingATP
TgeneEGFRchr16:67576379chr7:55269015ENST00000344576016790_7910706.0Nucleotide bindingATP
TgeneEGFRchr16:67576379chr7:55269015ENST00000420316010718_7260406.0Nucleotide bindingATP
TgeneEGFRchr16:67576379chr7:55269015ENST00000420316010790_7910406.0Nucleotide bindingATP
TgeneEGFRchr16:67576379chr7:55269015ENST00000275493028688_70401211.0RegionNote=Important for dimerization%2C phosphorylation and activation
TgeneEGFRchr16:67576379chr7:55269015ENST00000342916016688_7040629.0RegionNote=Important for dimerization%2C phosphorylation and activation
TgeneEGFRchr16:67576379chr7:55269015ENST00000344576016688_7040706.0RegionNote=Important for dimerization%2C phosphorylation and activation
TgeneEGFRchr16:67576379chr7:55269015ENST00000420316010688_7040406.0RegionNote=Important for dimerization%2C phosphorylation and activation
TgeneEGFRchr16:67576379chr7:55269015ENST00000275493028390_60001211.0RepeatNote=Approximate
TgeneEGFRchr16:67576379chr7:55269015ENST0000027549302875_30001211.0RepeatNote=Approximate
TgeneEGFRchr16:67576379chr7:55269015ENST00000342916016390_6000629.0RepeatNote=Approximate
TgeneEGFRchr16:67576379chr7:55269015ENST0000034291601675_3000629.0RepeatNote=Approximate
TgeneEGFRchr16:67576379chr7:55269015ENST00000344576016390_6000706.0RepeatNote=Approximate
TgeneEGFRchr16:67576379chr7:55269015ENST0000034457601675_3000706.0RepeatNote=Approximate
TgeneEGFRchr16:67576379chr7:55269015ENST00000420316010390_6000406.0RepeatNote=Approximate
TgeneEGFRchr16:67576379chr7:55269015ENST0000042031601075_3000406.0RepeatNote=Approximate
TgeneEGFRchr16:67576379chr7:55269015ENST0000027549302825_64501211.0Topological domainExtracellular
TgeneEGFRchr16:67576379chr7:55269015ENST00000275493028669_121001211.0Topological domainCytoplasmic
TgeneEGFRchr16:67576379chr7:55269015ENST0000034291601625_6450629.0Topological domainExtracellular
TgeneEGFRchr16:67576379chr7:55269015ENST00000342916016669_12100629.0Topological domainCytoplasmic
TgeneEGFRchr16:67576379chr7:55269015ENST0000034457601625_6450706.0Topological domainExtracellular
TgeneEGFRchr16:67576379chr7:55269015ENST00000344576016669_12100706.0Topological domainCytoplasmic
TgeneEGFRchr16:67576379chr7:55269015ENST0000042031601025_6450406.0Topological domainExtracellular
TgeneEGFRchr16:67576379chr7:55269015ENST00000420316010669_12100406.0Topological domainCytoplasmic
TgeneEGFRchr16:67576379chr7:55269015ENST00000275493028646_66801211.0TransmembraneHelical
TgeneEGFRchr16:67576379chr7:55269015ENST00000342916016646_6680629.0TransmembraneHelical
TgeneEGFRchr16:67576379chr7:55269015ENST00000344576016646_6680706.0TransmembraneHelical
TgeneEGFRchr16:67576379chr7:55269015ENST00000420316010646_6680406.0TransmembraneHelical

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneFAM65Achr16:67576379chr7:55269015ENST00000042381-12289_11401220.0Coiled coilOntology_term=ECO:0000255
HgeneFAM65Achr16:67576379chr7:55269015ENST00000379312-12289_11401224.0Coiled coilOntology_term=ECO:0000255
HgeneFAM65Achr16:67576379chr7:55269015ENST00000422602-12289_11401240.0Coiled coilOntology_term=ECO:0000255
HgeneFAM65Achr16:67576379chr7:55269015ENST00000428437-12289_11401234.0Coiled coilOntology_term=ECO:0000255
HgeneFAM65Achr16:67576379chr7:55269015ENST00000042381-122481_76701220.0Compositional biasNote=Pro-rich
HgeneFAM65Achr16:67576379chr7:55269015ENST00000379312-122481_76701224.0Compositional biasNote=Pro-rich
HgeneFAM65Achr16:67576379chr7:55269015ENST00000422602-122481_76701240.0Compositional biasNote=Pro-rich
HgeneFAM65Achr16:67576379chr7:55269015ENST00000428437-122481_76701234.0Compositional biasNote=Pro-rich


Top

Fusion Gene Sequence for FAM65A-EGFR


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.
>In-frame_ENST00000379312_ENST00000455089_BF844939_FAM65A_chr16_67576379_-_EGFR_chr7_55269015_length(transcript)=2642nt_BP=2001nt
GGCGCCTGCGGCGGCGACAGCGGCAGCTGCGGCGCGACCAGGCCGGGCACCTCCGAGCGCAAGGACAGCGCGAGGTCCGCGCAGCCCAGC
GCAGCCATGGAGCCCCGCGCGGACTCACTCTATGATGTCCCTGTCGGTGCGGCCGCAGCGCCGTCTGCTCAGCGCCCGGGTCAATAGGAG
CCAGTCCTTCGCAGGCGTCCTCGGCAGCCACGAGCGGGGGCCCAGCCTCTCCTTCAGGAGTTTCCCGGTCTTCAGCCCGCCGGGGCCCCC
ACGGAAGCCCCCCGCGCTCTCCCGAGTGTCCAGGATGTTTTCCGTGGCTCACCCAGCCGCCAAGGTGCCGCAGCCCGAGCGGCTGGACCT
GGTGTACACGGCGCTGAAGCGGGGCCTGACGGCCTACTTGGAAGTGCACCAGCAGGAGCAAGAGAAACTCCAGGGGCAGATAAGGGAGTC
CAAGAGGAATTCCCGCTTGGGCTTCCTGTATGATCTGGACAAGCAAGTCAAGTCCATTGAACGCTTCCTGCGACGACTGGAGTTCCATGC
CAGCAAGATCGATGAGCTGTATGAGGCATACTGTGTCCAGCGGCGTCTCCGGGATGGTGCCTACAACATGGTCCGTGCCTACACCACTGG
GTCCCCGGGAAGCCGAGAGGCCCGGGACAGCCTGGCAGAGGCCACTCGGGGGCATCGCGAGTACACGGAGAGCATGTGTCTGCTGGAGAG
CGAGCTGGAGGCACAGCTGGGCGAGTTTCATCTCCGAATGAAAGGGCTGGCTGGCTTCGCCAGGCTGTGTGTAGGCGATCAGTATGAGAT
CTGCATGAAATATGGGCGTCAGCGCTGGAAACTACGGGGCCGAATTGAGGGTAGTGGAAAGCAGGTGTGGGACAGTGAAGAAACCATCTT
TCTCCCTCTACTCACGGAATTTCTGTCTATTAAGGTGACAGAACTGAAGGGCCTGGCCAACCATGTGGTTGTGGGCAGTGTCTCCTGTGA
GACCAAGGACCTGTTTGCCGCCCTGCCCCAGGTTGTGGCTGTGGATATCAATGACCTTGGTACCATCAAGCTCAGCCTGGAAGTCACATG
GAGCCCCTTCGACAAGGATGACCAGCCCTCAGCTGCTTCTTCTGTCAACAAGGCCTCCACAGTCACCAAGCGCTTCTCCACCTATAGCCA
GAGCCCACCGGACACACCCTCACTTCGGGAACAGGCTTTCTATGCCCCCTCACTCACACTACTACAGGCTCCACCCACAAGCCCATAATC
TCTACCCTTACTACTACAGGCCCTACCCTCAATATCATAGGCCCAGTCCAGACTACCACAAGCCCCACCCACACTATGCCAAGCCCTACC
CATACCACAGCAAGCCCCACTCATACTTCCACAAGCCCCACCCATACCCCCACAAGTCCCACCCACAAAACCAGTATGTCACCTCCCACC
ACTACAAGTCCTACCCCCAGTGGTATGGGCCTAGTCCAGACTGCCACAAGTCCCACCCATCCTACCACAAGCCCCACCCATCCCACCACA
AGCCCCATCCTTATAAATGTAAGCCCTTCCACTTCTCTAGAACTTGCTACCCTCTCCAGCCCCTCCAAACACTCAGACCCCACCCTCCCA
GGCACTGACTCCCTTCCCTGTAGTCCCCCAGTCTCCAATTCCTACACTCAGGCAGACCCTATGGCCCCCAGAACTCCCCACCCAAGTCCT
GCCCATTCCAGTAGGAAACCCCTCACAAGCCCTGCCCCAGATCCCTCAGAGTCTACGGTTCAGAGTCTAAGCCCCACTCCCTCACCCCCA
ACCCCTGCACCCCAGCATTCAGACCTTTGCCTGGCCATGGCTGTCCAGACCCCAGTCCCAACGGCAGCCGGAGGGTCTGGGGACAGGAGC
CTGGAGGAGGCACTGGGGGCCCTAATGGCTGCCCTGGATGACTACCGTGGCCAGTTTCCTGAGCTGCAGGGCCTGGAGCAGGAGGTGACC
CGCCTAGAAAGTCTGCTCATGTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCAACCAGCAACAATTCCACCGTGGCTTGCATT
GATAGAAATGGGCTGCAAAGCTGTCCCATCAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGAC
AGCATAGACGACACCTTCCTCCCAGTGCCTGGTGAGTGGCTTGTCTGGAAACAGTCCTGCTCCTCAACCTCCTCGACCCACTCAGCAGCA
GCCAGTCTCCAGTGTCCAAGCCAGGTGCTCCCTCCAGCATCTCCAGAGGGGGAAACAGTGGCAGATTTGCAGACACAGTGAAGGGCGTAA
GGAGCAGATAAACACATGACCGAGCCTGCACAAGCTCTTTGTTGTGTCTGGTTGTTTGCTGTACCTCTGTTGTAAGAATGAATCTGCAAA
ATTTCTAGCTTATGAAGCAAATCACGGACATACACATCTGTGTGTGTGAGTGTTCATGATGTGTGTACATCTGTGTATGTGTGTGTGTGT
ATGTGTGTGTTTGTGACAGATTTGATCCCTGTTCTCTCTGCTGGCTCTATCTTGACCTGTGAAACGTATATTTAACTAATTAAATATTAG

>In-frame_ENST00000379312_ENST00000455089_BF844939_FAM65A_chr16_67576379_-_EGFR_chr7_55269015_length(amino acids)=378AA_start in transcript=121_stop in transcript=1257
MMSLSVRPQRRLLSARVNRSQSFAGVLGSHERGPSLSFRSFPVFSPPGPPRKPPALSRVSRMFSVAHPAAKVPQPERLDLVYTALKRGLT
AYLEVHQQEQEKLQGQIRESKRNSRLGFLYDLDKQVKSIERFLRRLEFHASKIDELYEAYCVQRRLRDGAYNMVRAYTTGSPGSREARDS
LAEATRGHREYTESMCLLESELEAQLGEFHLRMKGLAGFARLCVGDQYEICMKYGRQRWKLRGRIEGSGKQVWDSEETIFLPLLTEFLSI
KVTELKGLANHVVVGSVSCETKDLFAALPQVVAVDINDLGTIKLSLEVTWSPFDKDDQPSAASSVNKASTVTKRFSTYSQSPPDTPSLRE

--------------------------------------------------------------
>In-frame_ENST00000042381_ENST00000455089_BF844939_FAM65A_chr16_67576379_-_EGFR_chr7_55269015_length(transcript)=2577nt_BP=1936nt
CGAGCGCAAGGACAGCGCGAGGTCCGCGCAGCCCAGCGCAGCCATGGAGCCCCGCGCGGACTCACTCTATGATGTCCCTGTCGGTGCGGC
CGCAGCGCCGTCTGCTCAGCGCCCGGGTCAATAGGAGCCAGTCCTTCGCAGGCGTCCTCGGCAGCCACGAGCGGGGGCCCAGGAGTTTCC
CGGTCTTCAGCCCGCCGGGGCCCCCACGGAAGCCCCCCGCGCTCTCCCGAGTGTCCAGGATGTTTTCCGTGGCTCACCCAGCCGCCAAGG
TGCCGCAGCCCGAGCGGCTGGACCTGGTGTACACGGCGCTGAAGCGGGGCCTGACGGCCTACTTGGAAGTGCACCAGCAGGAGCAAGAGA
AACTCCAGGGGCAGATAAGGGAGTCCAAGAGGAATTCCCGCTTGGGCTTCCTGTATGATCTGGACAAGCAAGTCAAGTCCATTGAACGCT
TCCTGCGACGACTGGAGTTCCATGCCAGCAAGATCGATGAGCTGTATGAGGCATACTGTGTCCAGCGGCGTCTCCGGGATGGTGCCTACA
ACATGGTCCGTGCCTACACCACTGGGTCCCCGGGAAGCCGAGAGGCCCGGGACAGCCTGGCAGAGGCCACTCGGGGGCATCGCGAGTACA
CGGAGAGCATGTGTCTGCTGGAGAGCGAGCTGGAGGCACAGCTGGGCGAGTTTCATCTCCGAATGAAAGGGCTGGCTGGCTTCGCCAGGC
TGTGTGTAGGCGATCAGTATGAGATCTGCATGAAATATGGGCGTCAGCGCTGGAAACTACGGGGCCGAATTGAGGGTAGTGGAAAGCAGG
TGTGGGACAGTGAAGAAACCATCTTTCTCCCTCTACTCACGGAATTTCTGTCTATTAAGGTGACAGAACTGAAGGGCCTGGCCAACCATG
TGGTTGTGGGCAGTGTCTCCTGTGAGACCAAGGACCTGTTTGCCGCCCTGCCCCAGGTTGTGGCTGTGGATATCAATGACCTTGGTACCA
TCAAGCTCAGCCTGGAAGTCACATGGAGCCCCTTCGACAAGGATGACCAGCCCTCAGCTGCTTCTTCTGTCAACAAGGCCTCCACAGTCA
CCAAGCGCTTCTCCACCTATAGCCAGAGCCCACCGGACACACCCTCACTTCGGGAACAGGCTTTCTATGCCCCCTCACTCACACTACTAC
AGGCTCCACCCACAAGCCCATAATCTCTACCCTTACTACTACAGGCCCTACCCTCAATATCATAGGCCCAGTCCAGACTACCACAAGCCC
CACCCACACTATGCCAAGCCCTACCCATACCACAGCAAGCCCCACTCATACTTCCACAAGCCCCACCCATACCCCCACAAGTCCCACCCA
CAAAACCAGTATGTCACCTCCCACCACTACAAGTCCTACCCCCAGTGGTATGGGCCTAGTCCAGACTGCCACAAGTCCCACCCATCCTAC
CACAAGCCCCACCCATCCCACCACAAGCCCCATCCTTATAAATGTAAGCCCTTCCACTTCTCTAGAACTTGCTACCCTCTCCAGCCCCTC
CAAACACTCAGACCCCACCCTCCCAGGCACTGACTCCCTTCCCTGTAGTCCCCCAGTCTCCAATTCCTACACTCAGGCAGACCCTATGGC
CCCCAGAACTCCCCACCCAAGTCCTGCCCATTCCAGTAGGAAACCCCTCACAAGCCCTGCCCCAGATCCCTCAGAGTCTACGGTTCAGAG
TCTAAGCCCCACTCCCTCACCCCCAACCCCTGCACCCCAGCATTCAGACCTTTGCCTGGCCATGGCTGTCCAGACCCCAGTCCCAACGGC
AGCCGGAGGGTCTGGGGACAGGAGCCTGGAGGAGGCACTGGGGGCCCTAATGGCTGCCCTGGATGACTACCGTGGCCAGTTTCCTGAGCT
GCAGGGCCTGGAGCAGGAGGTGACCCGCCTAGAAAGTCTGCTCATGTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCAACCAG
CAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATCAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGA
CCCCACAGGCGCCTTGACTGAGGACAGCATAGACGACACCTTCCTCCCAGTGCCTGGTGAGTGGCTTGTCTGGAAACAGTCCTGCTCCTC
AACCTCCTCGACCCACTCAGCAGCAGCCAGTCTCCAGTGTCCAAGCCAGGTGCTCCCTCCAGCATCTCCAGAGGGGGAAACAGTGGCAGA
TTTGCAGACACAGTGAAGGGCGTAAGGAGCAGATAAACACATGACCGAGCCTGCACAAGCTCTTTGTTGTGTCTGGTTGTTTGCTGTACC
TCTGTTGTAAGAATGAATCTGCAAAATTTCTAGCTTATGAAGCAAATCACGGACATACACATCTGTGTGTGTGAGTGTTCATGATGTGTG
TACATCTGTGTATGTGTGTGTGTGTATGTGTGTGTTTGTGACAGATTTGATCCCTGTTCTCTCTGCTGGCTCTATCTTGACCTGTGAAAC

>In-frame_ENST00000042381_ENST00000455089_BF844939_FAM65A_chr16_67576379_-_EGFR_chr7_55269015_length(amino acids)=374AA_start in transcript=68_stop in transcript=1192
MMSLSVRPQRRLLSARVNRSQSFAGVLGSHERGPRSFPVFSPPGPPRKPPALSRVSRMFSVAHPAAKVPQPERLDLVYTALKRGLTAYLE
VHQQEQEKLQGQIRESKRNSRLGFLYDLDKQVKSIERFLRRLEFHASKIDELYEAYCVQRRLRDGAYNMVRAYTTGSPGSREARDSLAEA
TRGHREYTESMCLLESELEAQLGEFHLRMKGLAGFARLCVGDQYEICMKYGRQRWKLRGRIEGSGKQVWDSEETIFLPLLTEFLSIKVTE
LKGLANHVVVGSVSCETKDLFAALPQVVAVDINDLGTIKLSLEVTWSPFDKDDQPSAASSVNKASTVTKRFSTYSQSPPDTPSLREQAFY

--------------------------------------------------------------
>In-frame_ENST00000540839_ENST00000455089_BF844939_FAM65A_chr16_67576379_-_EGFR_chr7_55269015_length(transcript)=2789nt_BP=2148nt
ACAGCGCGAGGTCCGCGCAGCCCAGCGCAGCCATGGTGAGCCCTGAGTCCGGCCTCCCCTACAGACCCTCCCCAGCCAGTTCTAACGTGT
GTCCAGGCTGGCCGCCCCAGCACCTACTGTGCGCAGCCTCGTGTAACAATACTTGTGCCCTGGCTGCAGTCTGCGGGGCCGCGCCCTGGG
CCTGCCGCATTCGGCCAACGCACAGCATCTGAGGAGGGTTATGACCATCTGGCAGATGCAGAAACAGGCCCAGAGAGGGAGCCCCGCGCG
GACTCACTCTATGATGTCCCTGTCGGTGCGGCCGCAGCGCCGTCTGCTCAGCGCCCGGGTCAATAGGAGCCAGTCCTTCGCAGGCGTCCT
CGGCAGCCACGAGCGGGGGCCCAGGAGTTTCCCGGTCTTCAGCCCGCCGGGGCCCCCACGGAAGCCCCCCGCGCTCTCCCGAGTGTCCAG
GATGTTTTCCGTGGCTCACCCAGCCGCCAAGGTGCCGCAGCCCGAGCGGCTGGACCTGGTGTACACGGCGCTGAAGCGGGGCCTGACGGC
CTACTTGGAAGTGCACCAGCAGGAGCAAGAGAAACTCCAGGGGCAGATAAGGGAGTCCAAGAGGAATTCCCGCTTGGGCTTCCTGTATGA
TCTGGACAAGCAAGTCAAGTCCATTGAACGCTTCCTGCGACGACTGGAGTTCCATGCCAGCAAGATCGATGAGCTGTATGAGGCATACTG
TGTCCAGCGGCGTCTCCGGGATGGTGCCTACAACATGGTCCGTGCCTACACCACTGGGTCCCCGGGAAGCCGAGAGGCCCGGGACAGCCT
GGCAGAGGCCACTCGGGGGCATCGCGAGTACACGGAGAGCATGTGTCTGCTGGAGAGCGAGCTGGAGGCACAGCTGGGCGAGTTTCATCT
CCGAATGAAAGGGCTGGCTGGCTTCGCCAGGCTGTGTGTAGGCGATCAGTATGAGATCTGCATGAAATATGGGCGTCAGCGCTGGAAACT
ACGGGGCCGAATTGAGGGTAGTGGAAAGCAGGTGTGGGACAGTGAAGAAACCATCTTTCTCCCTCTACTCACGGAATTTCTGTCTATTAA
GGTGACAGAACTGAAGGGCCTGGCCAACCATGTGGTTGTGGGCAGTGTCTCCTGTGAGACCAAGGACCTGTTTGCCGCCCTGCCCCAGGT
TGTGGCTGTGGATATCAATGACCTTGGTACCATCAAGCTCAGCCTGGAAGTCACATGGAGCCCCTTCGACAAGGATGACCAGCCCTCAGC
TGCTTCTTCTGTCAACAAGGCCTCCACAGTCACCAAGCGCTTCTCCACCTATAGCCAGAGCCCACCGGACACACCCTCACTTCGGGAACA
GGCTTTCTATGCCCCCTCACTCACACTACTACAGGCTCCACCCACAAGCCCATAATCTCTACCCTTACTACTACAGGCCCTACCCTCAAT
ATCATAGGCCCAGTCCAGACTACCACAAGCCCCACCCACACTATGCCAAGCCCTACCCATACCACAGCAAGCCCCACTCATACTTCCACA
AGCCCCACCCATACCCCCACAAGTCCCACCCACAAAACCAGTATGTCACCTCCCACCACTACAAGTCCTACCCCCAGTGGTATGGGCCTA
GTCCAGACTGCCACAAGTCCCACCCATCCTACCACAAGCCCCACCCATCCCACCACAAGCCCCATCCTTATAAATGTAAGCCCTTCCACT
TCTCTAGAACTTGCTACCCTCTCCAGCCCCTCCAAACACTCAGACCCCACCCTCCCAGGCACTGACTCCCTTCCCTGTAGTCCCCCAGTC
TCCAATTCCTACACTCAGGCAGACCCTATGGCCCCCAGAACTCCCCACCCAAGTCCTGCCCATTCCAGTAGGAAACCCCTCACAAGCCCT
GCCCCAGATCCCTCAGAGTCTACGGTTCAGAGTCTAAGCCCCACTCCCTCACCCCCAACCCCTGCACCCCAGCATTCAGACCTTTGCCTG
GCCATGGCTGTCCAGACCCCAGTCCCAACGGCAGCCGGAGGGTCTGGGGACAGGAGCCTGGAGGAGGCACTGGGGGCCCTAATGGCTGCC
CTGGATGACTACCGTGGCCAGTTTCCTGAGCTGCAGGGCCTGGAGCAGGAGGTGACCCGCCTAGAAAGTCTGCTCATGTCCACGTCACGG
ACTCCCCTCCTGAGCTCTCTGAGTGCAACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATCAAG
GAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGACAGCATAGACGACACCTTCCTCCCAGTGCCTGGT
GAGTGGCTTGTCTGGAAACAGTCCTGCTCCTCAACCTCCTCGACCCACTCAGCAGCAGCCAGTCTCCAGTGTCCAAGCCAGGTGCTCCCT
CCAGCATCTCCAGAGGGGGAAACAGTGGCAGATTTGCAGACACAGTGAAGGGCGTAAGGAGCAGATAAACACATGACCGAGCCTGCACAA
GCTCTTTGTTGTGTCTGGTTGTTTGCTGTACCTCTGTTGTAAGAATGAATCTGCAAAATTTCTAGCTTATGAAGCAAATCACGGACATAC
ACATCTGTGTGTGTGAGTGTTCATGATGTGTGTACATCTGTGTATGTGTGTGTGTGTATGTGTGTGTTTGTGACAGATTTGATCCCTGTT

>In-frame_ENST00000540839_ENST00000455089_BF844939_FAM65A_chr16_67576379_-_EGFR_chr7_55269015_length(amino acids)=420AA_start in transcript=142_stop in transcript=1404
MCPGCSLRGRALGLPHSANAQHLRRVMTIWQMQKQAQRGSPARTHSMMSLSVRPQRRLLSARVNRSQSFAGVLGSHERGPRSFPVFSPPG
PPRKPPALSRVSRMFSVAHPAAKVPQPERLDLVYTALKRGLTAYLEVHQQEQEKLQGQIRESKRNSRLGFLYDLDKQVKSIERFLRRLEF
HASKIDELYEAYCVQRRLRDGAYNMVRAYTTGSPGSREARDSLAEATRGHREYTESMCLLESELEAQLGEFHLRMKGLAGFARLCVGDQY
EICMKYGRQRWKLRGRIEGSGKQVWDSEETIFLPLLTEFLSIKVTELKGLANHVVVGSVSCETKDLFAALPQVVAVDINDLGTIKLSLEV

--------------------------------------------------------------
>In-frame_ENST00000422602_ENST00000455089_BF844939_FAM65A_chr16_67576379_-_EGFR_chr7_55269015_length(transcript)=2665nt_BP=2024nt
AGCCTCGTGTAACAATACTTGTGCCCTGGCTGCAGTCTGCGGGGCCGCGCCCTGGGCCTGCCGCATTCGGCCAACGCACAGCATCTGAGG
AGGGTTATGACCATCTGGCAGATGCAGAAACAGGCCCAGAGAGGGAGCCCCGCGCGGACTCACTCTATGATGTCCCTGTCGGTGCGGCCG
CAGCGCCGTCTGCTCAGCGCCCGGGTCAATAGGAGCCAGTCCTTCGCAGGCGTCCTCGGCAGCCACGAGCGGGGGCCCAGGAGTTTCCCG
GTCTTCAGCCCGCCGGGGCCCCCACGGAAGCCCCCCGCGCTCTCCCGAGTGTCCAGGATGTTTTCCGTGGCTCACCCAGCCGCCAAGGTG
CCGCAGCCCGAGCGGCTGGACCTGGTGTACACGGCGCTGAAGCGGGGCCTGACGGCCTACTTGGAAGTGCACCAGCAGGAGCAAGAGAAA
CTCCAGGGGCAGATAAGGGAGTCCAAGAGGAATTCCCGCTTGGGCTTCCTGTATGATCTGGACAAGCAAGTCAAGTCCATTGAACGCTTC
CTGCGACGACTGGAGTTCCATGCCAGCAAGATCGATGAGCTGTATGAGGCATACTGTGTCCAGCGGCGTCTCCGGGATGGTGCCTACAAC
ATGGTCCGTGCCTACACCACTGGGTCCCCGGGAAGCCGAGAGGCCCGGGACAGCCTGGCAGAGGCCACTCGGGGGCATCGCGAGTACACG
GAGAGCATGTGTCTGCTGGAGAGCGAGCTGGAGGCACAGCTGGGCGAGTTTCATCTCCGAATGAAAGGGCTGGCTGGCTTCGCCAGGCTG
TGTGTAGGCGATCAGTATGAGATCTGCATGAAATATGGGCGTCAGCGCTGGAAACTACGGGGCCGAATTGAGGGTAGTGGAAAGCAGGTG
TGGGACAGTGAAGAAACCATCTTTCTCCCTCTACTCACGGAATTTCTGTCTATTAAGGTGACAGAACTGAAGGGCCTGGCCAACCATGTG
GTTGTGGGCAGTGTCTCCTGTGAGACCAAGGACCTGTTTGCCGCCCTGCCCCAGGTTGTGGCTGTGGATATCAATGACCTTGGTACCATC
AAGCTCAGCCTGGAAGTCACATGGAGCCCCTTCGACAAGGATGACCAGCCCTCAGCTGCTTCTTCTGTCAACAAGGCCTCCACAGTCACC
AAGCGCTTCTCCACCTATAGCCAGAGCCCACCGGACACACCCTCACTTCGGGAACAGGCTTTCTATGCCCCCTCACTCACACTACTACAG
GCTCCACCCACAAGCCCATAATCTCTACCCTTACTACTACAGGCCCTACCCTCAATATCATAGGCCCAGTCCAGACTACCACAAGCCCCA
CCCACACTATGCCAAGCCCTACCCATACCACAGCAAGCCCCACTCATACTTCCACAAGCCCCACCCATACCCCCACAAGTCCCACCCACA
AAACCAGTATGTCACCTCCCACCACTACAAGTCCTACCCCCAGTGGTATGGGCCTAGTCCAGACTGCCACAAGTCCCACCCATCCTACCA
CAAGCCCCACCCATCCCACCACAAGCCCCATCCTTATAAATGTAAGCCCTTCCACTTCTCTAGAACTTGCTACCCTCTCCAGCCCCTCCA
AACACTCAGACCCCACCCTCCCAGGCACTGACTCCCTTCCCTGTAGTCCCCCAGTCTCCAATTCCTACACTCAGGCAGACCCTATGGCCC
CCAGAACTCCCCACCCAAGTCCTGCCCATTCCAGTAGGAAACCCCTCACAAGCCCTGCCCCAGATCCCTCAGAGTCTACGGTTCAGAGTC
TAAGCCCCACTCCCTCACCCCCAACCCCTGCACCCCAGCATTCAGACCTTTGCCTGGCCATGGCTGTCCAGACCCCAGTCCCAACGGCAG
CCGGAGGGTCTGGGGACAGGAGCCTGGAGGAGGCACTGGGGGCCCTAATGGCTGCCCTGGATGACTACCGTGGCCAGTTTCCTGAGCTGC
AGGGCCTGGAGCAGGAGGTGACCCGCCTAGAAAGTCTGCTCATGTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCAACCAGCA
ACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATCAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACC
CCACAGGCGCCTTGACTGAGGACAGCATAGACGACACCTTCCTCCCAGTGCCTGGTGAGTGGCTTGTCTGGAAACAGTCCTGCTCCTCAA
CCTCCTCGACCCACTCAGCAGCAGCCAGTCTCCAGTGTCCAAGCCAGGTGCTCCCTCCAGCATCTCCAGAGGGGGAAACAGTGGCAGATT
TGCAGACACAGTGAAGGGCGTAAGGAGCAGATAAACACATGACCGAGCCTGCACAAGCTCTTTGTTGTGTCTGGTTGTTTGCTGTACCTC
TGTTGTAAGAATGAATCTGCAAAATTTCTAGCTTATGAAGCAAATCACGGACATACACATCTGTGTGTGTGAGTGTTCATGATGTGTGTA
CATCTGTGTATGTGTGTGTGTGTATGTGTGTGTTTGTGACAGATTTGATCCCTGTTCTCTCTGCTGGCTCTATCTTGACCTGTGAAACGT

>In-frame_ENST00000422602_ENST00000455089_BF844939_FAM65A_chr16_67576379_-_EGFR_chr7_55269015_length(amino acids)=420AA_start in transcript=18_stop in transcript=1280
MCPGCSLRGRALGLPHSANAQHLRRVMTIWQMQKQAQRGSPARTHSMMSLSVRPQRRLLSARVNRSQSFAGVLGSHERGPRSFPVFSPPG
PPRKPPALSRVSRMFSVAHPAAKVPQPERLDLVYTALKRGLTAYLEVHQQEQEKLQGQIRESKRNSRLGFLYDLDKQVKSIERFLRRLEF
HASKIDELYEAYCVQRRLRDGAYNMVRAYTTGSPGSREARDSLAEATRGHREYTESMCLLESELEAQLGEFHLRMKGLAGFARLCVGDQY
EICMKYGRQRWKLRGRIEGSGKQVWDSEETIFLPLLTEFLSIKVTELKGLANHVVVGSVSCETKDLFAALPQVVAVDINDLGTIKLSLEV

--------------------------------------------------------------
>In-frame_ENST00000428437_ENST00000455089_BF844939_FAM65A_chr16_67576379_-_EGFR_chr7_55269015_length(transcript)=2676nt_BP=2035nt
GAGGAGCCGAAGCCGAGCCAGAGCCGCTGGGAGCGAGCCCGGAGCCCAGCCGGGCGGCTCGAAGTGGCCAGGGCCGGAAGGTCCGCGGGG
GGCGAGCGCGGGTCGGGGGCCGTCCCGGACCCACCATGAACACCAAGAAGAGAGGGAGCCCCGCGCGGACTCACTCTATGATGTCCCTGT
CGGTGCGGCCGCAGCGCCGTCTGCTCAGCGCCCGGGTCAATAGGAGCCAGTCCTTCGCAGGCGTCCTCGGCAGCCACGAGCGGGGGCCCA
GGAGTTTCCCGGTCTTCAGCCCGCCGGGGCCCCCACGGAAGCCCCCCGCGCTCTCCCGAGTGTCCAGGATGTTTTCCGTGGCTCACCCAG
CCGCCAAGGTGCCGCAGCCCGAGCGGCTGGACCTGGTGTACACGGCGCTGAAGCGGGGCCTGACGGCCTACTTGGAAGTGCACCAGCAGG
AGCAAGAGAAACTCCAGGGGCAGATAAGGGAGTCCAAGAGGAATTCCCGCTTGGGCTTCCTGTATGATCTGGACAAGCAAGTCAAGTCCA
TTGAACGCTTCCTGCGACGACTGGAGTTCCATGCCAGCAAGATCGATGAGCTGTATGAGGCATACTGTGTCCAGCGGCGTCTCCGGGATG
GTGCCTACAACATGGTCCGTGCCTACACCACTGGGTCCCCGGGAAGCCGAGAGGCCCGGGACAGCCTGGCAGAGGCCACTCGGGGGCATC
GCGAGTACACGGAGAGCATGTGTCTGCTGGAGAGCGAGCTGGAGGCACAGCTGGGCGAGTTTCATCTCCGAATGAAAGGGCTGGCTGGCT
TCGCCAGGCTGTGTGTAGGCGATCAGTATGAGATCTGCATGAAATATGGGCGTCAGCGCTGGAAACTACGGGGCCGAATTGAGGGTAGTG
GAAAGCAGGTGTGGGACAGTGAAGAAACCATCTTTCTCCCTCTACTCACGGAATTTCTGTCTATTAAGGTGACAGAACTGAAGGGCCTGG
CCAACCATGTGGTTGTGGGCAGTGTCTCCTGTGAGACCAAGGACCTGTTTGCCGCCCTGCCCCAGGTTGTGGCTGTGGATATCAATGACC
TTGGTACCATCAAGCTCAGCCTGGAAGTCACATGGAGCCCCTTCGACAAGGATGACCAGCCCTCAGCTGCTTCTTCTGTCAACAAGGCCT
CCACAGTCACCAAGCGCTTCTCCACCTATAGCCAGAGCCCACCGGACACACCCTCACTTCGGGAACAGGCTTTCTATGCCCCCTCACTCA
CACTACTACAGGCTCCACCCACAAGCCCATAATCTCTACCCTTACTACTACAGGCCCTACCCTCAATATCATAGGCCCAGTCCAGACTAC
CACAAGCCCCACCCACACTATGCCAAGCCCTACCCATACCACAGCAAGCCCCACTCATACTTCCACAAGCCCCACCCATACCCCCACAAG
TCCCACCCACAAAACCAGTATGTCACCTCCCACCACTACAAGTCCTACCCCCAGTGGTATGGGCCTAGTCCAGACTGCCACAAGTCCCAC
CCATCCTACCACAAGCCCCACCCATCCCACCACAAGCCCCATCCTTATAAATGTAAGCCCTTCCACTTCTCTAGAACTTGCTACCCTCTC
CAGCCCCTCCAAACACTCAGACCCCACCCTCCCAGGCACTGACTCCCTTCCCTGTAGTCCCCCAGTCTCCAATTCCTACACTCAGGCAGA
CCCTATGGCCCCCAGAACTCCCCACCCAAGTCCTGCCCATTCCAGTAGGAAACCCCTCACAAGCCCTGCCCCAGATCCCTCAGAGTCTAC
GGTTCAGAGTCTAAGCCCCACTCCCTCACCCCCAACCCCTGCACCCCAGCATTCAGACCTTTGCCTGGCCATGGCTGTCCAGACCCCAGT
CCCAACGGCAGCCGGAGGGTCTGGGGACAGGAGCCTGGAGGAGGCACTGGGGGCCCTAATGGCTGCCCTGGATGACTACCGTGGCCAGTT
TCCTGAGCTGCAGGGCCTGGAGCAGGAGGTGACCCGCCTAGAAAGTCTGCTCATGTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAG
TGCAACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATCAAGGAAGACAGCTTCTTGCAGCGATA
CAGCTCAGACCCCACAGGCGCCTTGACTGAGGACAGCATAGACGACACCTTCCTCCCAGTGCCTGGTGAGTGGCTTGTCTGGAAACAGTC
CTGCTCCTCAACCTCCTCGACCCACTCAGCAGCAGCCAGTCTCCAGTGTCCAAGCCAGGTGCTCCCTCCAGCATCTCCAGAGGGGGAAAC
AGTGGCAGATTTGCAGACACAGTGAAGGGCGTAAGGAGCAGATAAACACATGACCGAGCCTGCACAAGCTCTTTGTTGTGTCTGGTTGTT
TGCTGTACCTCTGTTGTAAGAATGAATCTGCAAAATTTCTAGCTTATGAAGCAAATCACGGACATACACATCTGTGTGTGTGAGTGTTCA
TGATGTGTGTACATCTGTGTATGTGTGTGTGTGTATGTGTGTGTTTGTGACAGATTTGATCCCTGTTCTCTCTGCTGGCTCTATCTTGAC

>In-frame_ENST00000428437_ENST00000455089_BF844939_FAM65A_chr16_67576379_-_EGFR_chr7_55269015_length(amino acids)=421AA_start in transcript=26_stop in transcript=1291
MGASPEPSRAARSGQGRKVRGGRARVGGRPGPTMNTKKRGSPARTHSMMSLSVRPQRRLLSARVNRSQSFAGVLGSHERGPRSFPVFSPP
GPPRKPPALSRVSRMFSVAHPAAKVPQPERLDLVYTALKRGLTAYLEVHQQEQEKLQGQIRESKRNSRLGFLYDLDKQVKSIERFLRRLE
FHASKIDELYEAYCVQRRLRDGAYNMVRAYTTGSPGSREARDSLAEATRGHREYTESMCLLESELEAQLGEFHLRMKGLAGFARLCVGDQ
YEICMKYGRQRWKLRGRIEGSGKQVWDSEETIFLPLLTEFLSIKVTELKGLANHVVVGSVSCETKDLFAALPQVVAVDINDLGTIKLSLE

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for FAM65A-EGFR


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for FAM65A-EGFR


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status
TgeneEGFRP00533DB00002CetuximabAntagonistBiotechApproved
TgeneEGFRP00533DB00002CetuximabAntagonistBiotechApproved
TgeneEGFRP00533DB00002CetuximabAntagonistBiotechApproved
TgeneEGFRP00533DB00002CetuximabAntagonistBiotechApproved
TgeneEGFRP00533DB05294VandetanibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB05294VandetanibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB05294VandetanibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB05294VandetanibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB08916AfatinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB08916AfatinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB08916AfatinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB08916AfatinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB09330OsimertinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB09330OsimertinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB09330OsimertinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB09330OsimertinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
TgeneEGFRP00533DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
TgeneEGFRP00533DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
TgeneEGFRP00533DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
TgeneEGFRP00533DB00317GefitinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00317GefitinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00317GefitinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00317GefitinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00530ErlotinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00530ErlotinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00530ErlotinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00530ErlotinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB01259LapatinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB01259LapatinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB01259LapatinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB01259LapatinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB01269PanitumumabSuppressorBiotechApproved|Investigational
TgeneEGFRP00533DB01269PanitumumabSuppressorBiotechApproved|Investigational
TgeneEGFRP00533DB01269PanitumumabSuppressorBiotechApproved|Investigational
TgeneEGFRP00533DB01269PanitumumabSuppressorBiotechApproved|Investigational
TgeneEGFRP00533DB09559NecitumumabAntagonistBiotechApproved|Investigational
TgeneEGFRP00533DB09559NecitumumabAntagonistBiotechApproved|Investigational
TgeneEGFRP00533DB09559NecitumumabAntagonistBiotechApproved|Investigational
TgeneEGFRP00533DB09559NecitumumabAntagonistBiotechApproved|Investigational
TgeneEGFRP00533DB11828NeratinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11828NeratinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11828NeratinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11828NeratinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11963DacomitinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11963DacomitinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11963DacomitinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11963DacomitinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB15035ZanubrutinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB15035ZanubrutinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB15035ZanubrutinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB15035ZanubrutinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00281LidocaineAntagonistSmall moleculeApproved|Vet_approved
TgeneEGFRP00533DB00281LidocaineAntagonistSmall moleculeApproved|Vet_approved
TgeneEGFRP00533DB00281LidocaineAntagonistSmall moleculeApproved|Vet_approved
TgeneEGFRP00533DB00281LidocaineAntagonistSmall moleculeApproved|Vet_approved

Top

Related Diseases for FAM65A-EGFR


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
TgeneEGFRC0007131Non-Small Cell Lung Carcinoma16CGI;CTD_human
TgeneEGFRC0024121Lung Neoplasms7CGI;CTD_human
TgeneEGFRC0242379Malignant neoplasm of lung7CGI;CTD_human
TgeneEGFRC0006142Malignant neoplasm of breast6CTD_human
TgeneEGFRC0678222Breast Carcinoma6CTD_human
TgeneEGFRC1257931Mammary Neoplasms, Human6CTD_human
TgeneEGFRC1458155Mammary Neoplasms6CTD_human
TgeneEGFRC4704874Mammary Carcinoma, Human6CTD_human
TgeneEGFRC0001418Adenocarcinoma5CTD_human
TgeneEGFRC0205641Adenocarcinoma, Basal Cell5CTD_human
TgeneEGFRC0205642Adenocarcinoma, Oxyphilic5CTD_human
TgeneEGFRC0205643Carcinoma, Cribriform5CTD_human
TgeneEGFRC0205644Carcinoma, Granular Cell5CTD_human
TgeneEGFRC0205645Adenocarcinoma, Tubular5CTD_human
TgeneEGFRC0334588Giant Cell Glioblastoma5CTD_human;ORPHANET
TgeneEGFRC0007137Squamous cell carcinoma3CTD_human
TgeneEGFRC0007873Uterine Cervical Neoplasm3CTD_human
TgeneEGFRC0014859Esophageal Neoplasms3CGI;CTD_human
TgeneEGFRC0017636Glioblastoma3CGI;CTD_human
TgeneEGFRC0018671Head and Neck Neoplasms3CGI;CTD_human
TgeneEGFRC0018675Head Neoplasms3CTD_human
TgeneEGFRC0024623Malignant neoplasm of stomach3CTD_human
TgeneEGFRC0027533Neck Neoplasms3CTD_human
TgeneEGFRC0027627Neoplasm Metastasis3CTD_human
TgeneEGFRC0033578Prostatic Neoplasms3CTD_human
TgeneEGFRC0038356Stomach Neoplasms3CTD_human
TgeneEGFRC0278996Malignant Head and Neck Neoplasm3CGI;CTD_human
TgeneEGFRC0376358Malignant neoplasm of prostate3CTD_human
TgeneEGFRC0546837Malignant neoplasm of esophagus3CGI;CTD_human
TgeneEGFRC0746787Cancer of Neck3CTD_human
TgeneEGFRC0751177Cancer of Head3CTD_human
TgeneEGFRC0887900Upper Aerodigestive Tract Neoplasms3CTD_human
TgeneEGFRC1621958Glioblastoma Multiforme3CTD_human
TgeneEGFRC1708349Hereditary Diffuse Gastric Cancer3CTD_human
TgeneEGFRC4048328cervical cancer3CTD_human
TgeneEGFRC0005684Malignant neoplasm of urinary bladder2CTD_human
TgeneEGFRC0005695Bladder Neoplasm2CTD_human
TgeneEGFRC0007102Malignant tumor of colon2CTD_human
TgeneEGFRC0009375Colonic Neoplasms2CTD_human
TgeneEGFRC0009402Colorectal Carcinoma2CTD_human
TgeneEGFRC0009404Colorectal Neoplasms2CTD_human
TgeneEGFRC0024668Mammary Neoplasms, Experimental2CTD_human
TgeneEGFRC0027626Neoplasm Invasiveness2CTD_human
TgeneEGFRC0027643Neoplasm Recurrence, Local2CTD_human
TgeneEGFRC0152013Adenocarcinoma of lung (disorder)2CGI;CTD_human
TgeneEGFRC0206726gliosarcoma2ORPHANET
TgeneEGFRC0919267ovarian neoplasm2CTD_human
TgeneEGFRC1140680Malignant neoplasm of ovary2CTD_human
TgeneEGFRC4015130INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 22CTD_human;GENOMICS_ENGLAND;UNIPROT
TgeneEGFRC0001973Alcoholic Intoxication, Chronic1PSYGENET
TgeneEGFRC0003865Arthritis, Adjuvant-Induced1CTD_human
TgeneEGFRC0005396Bile Duct Neoplasms1CTD_human
TgeneEGFRC0007097Carcinoma1CTD_human
TgeneEGFRC0007113Rectal Carcinoma1CTD_human
TgeneEGFRC0007193Cardiomyopathy, Dilated1CTD_human
TgeneEGFRC0011603Dermatitis1CTD_human
TgeneEGFRC0011860Diabetes Mellitus, Non-Insulin-Dependent1CTD_human
TgeneEGFRC0014175Endometriosis1CTD_human
TgeneEGFRC0016978gallbladder neoplasm1CTD_human
TgeneEGFRC0021655Insulin Resistance1CTD_human
TgeneEGFRC0022660Kidney Failure, Acute1CTD_human
TgeneEGFRC0024667Animal Mammary Neoplasms1CTD_human
TgeneEGFRC0024809Marijuana Abuse1PSYGENET
TgeneEGFRC0025500Mesothelioma1CTD_human
TgeneEGFRC0027439Nasopharyngeal Neoplasms1CTD_human
TgeneEGFRC0029463Osteosarcoma1CTD_human
TgeneEGFRC0030297Pancreatic Neoplasm1CTD_human
TgeneEGFRC0030354Papilloma1CTD_human
TgeneEGFRC0032580Adenomatous Polyposis Coli1CTD_human
TgeneEGFRC0034885Rectal Neoplasms1CTD_human
TgeneEGFRC0041696Unipolar Depression1PSYGENET
TgeneEGFRC0085548Autosomal Recessive Polycystic Kidney Disease1CTD_human
TgeneEGFRC0085762Alcohol abuse1PSYGENET
TgeneEGFRC0149925Small cell carcinoma of lung1CTD_human
TgeneEGFRC0153452Malignant neoplasm of gallbladder1CTD_human
TgeneEGFRC0205696Anaplastic carcinoma1CTD_human
TgeneEGFRC0205697Carcinoma, Spindle-Cell1CTD_human
TgeneEGFRC0205698Undifferentiated carcinoma1CTD_human
TgeneEGFRC0205699Carcinomatosis1CTD_human
TgeneEGFRC0205874Papilloma, Squamous Cell1CTD_human
TgeneEGFRC0205875Papillomatosis1CTD_human
TgeneEGFRC0206686Adrenocortical carcinoma1CTD_human
TgeneEGFRC0206698Cholangiocarcinoma1CTD_human
TgeneEGFRC0235874Disease Exacerbation1CTD_human
TgeneEGFRC0238301Cancer of Nasopharynx1CTD_human
TgeneEGFRC0263454Chloracne1CTD_human
TgeneEGFRC0269102Endometrioma1CTD_human
TgeneEGFRC0279626Squamous cell carcinoma of esophagus1CGI;CTD_human
TgeneEGFRC0345905Intrahepatic Cholangiocarcinoma1CTD_human
TgeneEGFRC0345967Malignant mesothelioma1CTD_human
TgeneEGFRC0346647Malignant neoplasm of pancreas1CTD_human
TgeneEGFRC0376634Craniofacial Abnormalities1CTD_human
TgeneEGFRC0740277Bile duct carcinoma1CTD_human
TgeneEGFRC0920563Insulin Sensitivity1CTD_human
TgeneEGFRC0971858Arthritis, Collagen-Induced1CTD_human
TgeneEGFRC0993582Arthritis, Experimental1CTD_human
TgeneEGFRC1257925Mammary Carcinoma, Animal1CTD_human
TgeneEGFRC1269683Major Depressive Disorder1PSYGENET
TgeneEGFRC1449563Cardiomyopathy, Familial Idiopathic1CTD_human
TgeneEGFRC1565662Acute Kidney Insufficiency1CTD_human
TgeneEGFRC2239176Liver carcinoma1CTD_human
TgeneEGFRC2609414Acute kidney injury1CTD_human
TgeneEGFRC2713442Polyposis, Adenomatous Intestinal1CTD_human
TgeneEGFRC2713443Familial Intestinal Polyposis1CTD_human
TgeneEGFRC3805278Extrahepatic Cholangiocarcinoma1CTD_human
TgeneEGFRC4751120Neonatal inflammatory skin and bowel disease1ORPHANET